Summary
Janssen-Cilag Pty Ltd (Janssen-Cilag) proposes to offer discounted Zytiga cancer treatment to patients with a particular class of prostate cancer on condition that the patients acquire the treatment from a centralised dispensing pharmacy, East Gosford Pharmacy, and utilise program administration services from Vivacity Health. Zytiga is approved for use by this class of patients by the Therapeutic Goods Administration but this use is not subsidised under the Pharmaceutical Benefits Scheme (the PBS). Janssen-Cilag proposes to continue this offer until Zytiga is listed on the PBS for the use of this class of patients.
